6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Consolidated Mail Outpatient Pharmacy (CMOP), has issued a Request for Information (RFI) for Domestic Pharmaceutical Manufacturing. This RFI, identified as 36C77026Q0061, seeks to identify domestic small and large businesses capable of manufacturing pharmaceutical end items and ancillary medical-surgical items for CMOP's Open Market (OM) purchases. The VA has a highest interest in Service-Disabled Veteran Owned Small Businesses (SDVOSB) and Veteran Owned Small Businesses (VOSB) manufacturers. Responses are due March 15, 2026, at 4:30 pm CT.
Purpose
This RFI is solely for market research and procurement planning. Its purpose is to:
- Identify domestic small and large business pharmaceutical manufacturers with efficient production capabilities.
- Gather information on manufacturers of pharmaceuticals and ancillary items for CMOP's OM purchases.
- Promote early exchanges of information to improve mutual understanding of Government needs and industry capabilities.
- Gain deeper insight into small business manufacturing considerations, with particular interest in SDVOSB and VOSB.
Scope of Interest
The VA is interested in manufacturers operating under NAICS codes 325412 (Pharmaceutical Preparation Manufacturing) and 325413 (In-Vitro Diagnostic Substance Manufacturing). CMOP requires a wide range of pharmaceutical and medical-surgical items, including but not limited to: ABALOPARATIDE, ACAMPROSATE CA, ARMODAFINIL, ARTIFICIAL SALIVA ORAL SPRAY, BREAST MILK STORAGE BAGS, BRIMONIDINE TARTRATE, CALCIUM/VITAMIN D CHEW TABS, CARBOXYMETHYLCELLULOSE NA, various catheters, CLINDAMYCIN, CLOMIPHENE CITRATE, COAL TAR SHAMPOO, COLESTIPOL HCL, DESONIDE, DORZOLAMIDE/TIMOLOL, DRESSINGS, DROSPIRENONE, DULOXETINE HCL, ELECTRODE PADS, ESOMEPRAZOLE, EYELID CLEANSER, FEMALE CONDOMS, FENOFIBRATE, FESOTERODINE FUMARATE, FOSINOPRIL NA, GALANTAMINE HYDROBROMIDE, GLIPIZIDE, HYDROCORTISONE ACETATE, IBUPROFEN, JASMIEL, LANSOPRAZOLE, LEG BAGS, LEVODOPA, LEVOFLOXICIN, METFORMIN, MINOCYCLINE HCL, NEBIVOLOL, ONE TOUCH ULTRA TEST STRIPS, NURSING DISPOSABLE PADS, PIOGLITAZONE HCL, PREDNISONE, PROPRANOLOL HCL, PYRIDOSTIGMINE BROMIDE, RESOURCE BENEPROTEIN PWDR, INFUSION SETS, SEVELAMER CARBONATE, SODIUM CHLORIDE, SUMATRIPTAN, UREA CREAM, ZINC OXIDE, and ZOLPIDEM TARTRATE. Manufacturers of other domestically produced pharmaceuticals are also encouraged to respond.
Submission Requirements
Interested manufacturers must submit a complete capability statement and response by March 15, 2026, at 4:30 pm CT. Submissions should include:
- Company Information: Name, physical address, point of contact, physical address of domestic manufacturing facility, socioeconomic status (e.g., SDVOSB, VOSB, 8(a)), business size, and SAM UEI Number.
- Product Information: List of domestically manufactured pharmaceuticals, FDA-approved NDC numbers, treatment usage, authorized distributors, and average cost for common prescription quantities.
- Operational Capability: Manufacturing facility production capacity, frequency of stockouts in the past 12 months, typical replenishment timelines, and commercial entities where items have been sold for large volume dispensing.
- Contracting Information: GSA/FSS/NAC contract numbers (if applicable) and suggested alternative NAICS or PSC codes.
- Compliance: Ability to meet federal, state, and local regulations, and capacity to support all seven CMOP sites if needed. Respondents must use the provided Excel Spreadsheet ('Manufacturer Inputs_Excel') for inputs. Responses should be emailed to Michael McAlhaney (michael.mcalhaney@va.gov) and Tresanna Tacia (tresanna.tacia@va.gov). The email subject line must start with the RFI Number 36C77026Q0061 followed by the generic pharmaceutical name.
Important Notes
This RFI is for information and planning purposes only and does not constitute a solicitation or commitment to award a contract. No funds have been authorized for this effort. All proprietary information will be handled accordingly. Respondents are responsible for all expenses associated with their response. Prospective contractors must be registered in the System for Award Management (SAM) database.